Haemophilia trials in Sweden

In Sweden 8 Also abroad 128

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
Where
Malmö
Age
18 years to 64 years
People
32 worldwide
Run by
Pfizer Inc.
See details and how to join2025-523660-21-00 · EU 2025-523660-21-00
Phase 3Taking people
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Where
Malmö
Age
18 years and over
People
173 worldwide
Run by
Pfizer
See details and how to joinNCT05568719
Phase 4Taking people
Treatment of Hemophilia A Patients With FVIII Inhibitors
Where
Malmo
People
120 worldwide
Run by
Emory University
See details and how to joinNCT04023019 · EU 2024-516741-39-00
Phase 1Taking people
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Where
Malmo, Solna
Age
18 years to 64 years
People
30 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00
No phaseTaking people
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Where
Malmö, Stockholm
People
4,000 worldwide
Run by
PedNet Haemophilia Research Foundation
See details and how to joinNCT02979119
No phaseTaking people
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Where
Solna
Age
7 years and over
People
20
Run by
Karolinska Institutet
See details and how to joinNCT02453542
Phase 2/3Enrolling by invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Where
Malmo
Age
18 years and over
People
56 worldwide
Run by
CSL Behring
See details and how to joinNCT05962398 · EU 2023-503765-37-00
Phase 1Taking people
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
Where
Lund
Age
18 years to 64 years
People
4 worldwide
Run by
Cell4Cure AB
See details and how to join2022-502030-12-01 · EU 2022-502030-12-01